The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Does The Forecasted Market Size Of The Rare Disease Genetic Testing Market Compare Between 2026 And 2030?
The rare disease genetic testing market has seen rapid expansion in recent years. It is anticipated to grow from $1.17 billion in 2025 to $1.33 billion in 2026, with a compound annual growth rate (CAGR) of 13.7%. The historical development of this market is attributable to improvements in genomic sequencing technologies, expansion of rare disease research initiatives, rising awareness of genetic disorders, availability of specialized diagnostic laboratories, and growth in clinical genetics programs.
The rare disease genetic testing market is projected to experience swift expansion in the coming years. This market is anticipated to reach $2.18 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.1%. This projected growth is primarily driven by factors such as the increasing demand for personalized medicine, growing investments in genomic data analytics, the expansion of population-scale genetic screening initiatives, the increasing integration of genetics into standard clinical care, and progress in bioinformatics platforms. Key trends expected during this forecast period involve the rising adoption of next-generation sequencing for rare diseases, the expanding application of AI-driven variant interpretation, the enlargement of comprehensive genetic testing panels, the increasing integration of genetic data into clinical decision systems, and a heightened emphasis on early and precise diagnosis.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27404&type=smp
What Core Drivers Are Transforming The Rare Disease Genetic Testing Market?
The escalating number of genetic disorders is projected to fuel the expansion of the rare disease genetic testing market moving forward. Genetic disorders are medical conditions resulting from irregularities in an individual’s deoxyribonucleic acid, which can be inherited from either parent or originate from novel mutations. The rise in genetic disorders is partly attributed to increasing parental age, as older parents face a higher probability of passing on genetic mutations to their children. Rare disease genetic testing aids in the diagnosis of genetic disorders by identifying specific mutations, thereby enabling accurate and early detection. This testing also supports personalized treatment planning, which improves patient care and enhances long-term health outcomes. For instance, in May 2024, according to the National Health Service, a UK-based government department, there are 17,000 people living with sickle cell disease, an inherited genetic blood disorder, with around 250 new cases diagnosed each year. Consequently, the increasing prevalence of genetic disorders is propelling the growth of the rare disease genetic testing market.
How Is The Rare Disease Genetic Testing Market Distributed Across Key Segments?
The rare disease genetic testing market covered in this report is segmented –
1) By Disease Type: Immunological Disorders, Cardiovascular Disorders, Neurological Disease, Endocrine And Metabolism Disorders Diseases, Hematological Diseases, Dermatological Disease, Other Disease Types
2) By Technology: Next-Generation Sequencing, Sanger Sequencing, Polymerase Chain Reaction Based Testing, Array Based Testing, Fluorescence In Situ Hybridization, Other Technologies
3) By Specialty: Molecular Genetic Tests, Chromosomal Genetic Tests, Biochemical Genetic Tests
4) By End-User: Hospitals And Clinics, Research Laboratories And Contract Research Organizations, Diagnostic Laboratories, Other End Users
Subsegments:
1) By Immunological Disorders: Autoimmune Disorders, Allergic Conditions, Primary Immunodeficiency Disorders, Inflammatory Disorders
2) By Cardiovascular Disorders: Congenital Heart Defects, Cardiomyopathies, Aortic Aneurysms, Pulmonary Hypertension
3) By Neurological Disease: Neurodegenerative Disorders, Neuromuscular Disorders, Epileptic Syndromes, Movement Disorders
4) By Endocrine And Metabolism Disorders Diseases: Inherited Metabolic Disorders, Thyroid Disorders, Adrenal Disorders, Diabetes Related Genetic Conditions
5) By Hematological Diseases: Hemophilia, Thalassemia, Sickle Cell Disease, Clotting Disorders
6) By Dermatological Disease: Genetic Skin Disorders, Connective Tissue Disorders, Pigmentary Disorders, Keratinization Disorders
7) By Other Disease Types: Skeletal Dysplasia, Renal Genetic Disorders, Ophthalmic Genetic Conditions, Gastrointestinal Genetic Conditions
Which Trends Are Guiding The Development Of The Rare Disease Genetic Testing Market?
Key players in the rare disease diagnostics market are concentrating on creating advanced solutions, including high-sensitivity whole genome sequencing (WGS) platforms, to elevate diagnostic precision, expand the scope of variant detection, and accelerate the identification of complex rare disorders. These high-sensitivity WGS platforms enable a comprehensive analysis of nearly all genetic variants responsible for diseases in a single test, thereby supporting earlier and more accurate diagnoses. For example, in April 2023, Centogene GmbH, a Germany-based rare disease company, launched CentoGenome, an improved next-generation sequencing (NGS)-based whole genome sequencing solution specifically designed for the diagnosis of rare and neurodegenerative diseases. The platform provides broad variant coverage, including Copy Number Variations (CNVs) related to spinal muscular atrophy (SMA) and complex pathogenic variants connected to Gaucher disease (GD) and GBA1-related Parkinson’s disease. Additionally, CentoGenome incorporates PCR-free technology to lessen sequencing bias in difficult genomic regions, leading to higher-quality data and profound insights into coding, regulatory, and intronic areas for more accurate clinical interpretation.
Which Organizations Are Operating Within The Rare Disease Genetic Testing Market?
Major companies operating in the rare disease genetic testing market are Thermo Fisher Scientific Inc., Quest Diagnostics Inc., Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., QIAGEN N.V., Natera Inc., OPKO Health Inc., Myriad Genetics Inc., Fulgent Genetics Inc., BioReference Laboratories Inc., Invitae Corporation, Ambry Genetics Corporation, Centogene N.V., Baylor Genetics Company, PreventionGenetics, Blueprint Genetics Oy, Artemis DNA Inc., BGI Genomics Co. Ltd., GeneDx Inc., Genomics England Ltd.
Access The Complete Rare Disease Genetic Testing Market Report:
https://www.thebusinessresearchcompany.com/report/rare-disease-genetic-testing-global-market-report
What Is The Largest Regional Market In The Rare Disease Genetic Testing Market?
North America was the largest region in the rare disease genetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease genetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Rare Disease Genetic Testing Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=27404&type=smp
Browse Through More Reports Similar to the Global Rare Disease Genetic Testing Market 2026, By The Business Research Company
Rare Diseases Treatment Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report
Clinical Diagnostics Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/clinical-diagnostics-global-market-report
Rare Kidney Diseases Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model